Q2 FY2026 EarningsQ2 FY26 results were mixed, with a solid top-line beat driven by TAVR and TMTT growth, but a significant miss on GAAP EPS due to non-recurring tax items. Revenue reached $1,741M (+13.6% YoY) vs. $1,699M expected, while GAAP EPS of $0.42 fell sharply below the $0.72 consensus. The variance was primarily driven by a $188.2M valuation allowance on California tax credits and $40M in investment impairments, partially offset by strong underlying demand in structural heart therapies.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Edwards Lifesciences(EW) the Revenue is 1.741 B (+13.63%), Beat estimate;the EBIT is 522.7 M (+20.8%), Beat estimate;the EPS is 0.42 (-25%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
1.74B13.63%
1.70B10.92%
+0.04B2.71%
EBITExceed expectations
0.52B20.80%
0.48B11.52%
+0.04B9.28%
EPSMiss expectations
0.4225.00%
0.7228.57%
-0.300053.57%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf